Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05517655 · ClinicalTrials.gov registry record · Phase 4
BEGIN Novel ImagiNG Biomarkers
A Phase 4 study of Cystic Fibrosis, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
- 3
- Study locations
NCT05517655 is a Phase 4 study of Cystic Fibrosis that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 44 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (75% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05517655, a Phase 4 study of Cystic Fibrosis, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
- 3
- Study locations
Study Summary
To determine the treatment effect of triple-combination therapy in 6-8 year olds after presumed FDA approval, using rapid structural and functional pulmonary and abdominal MRI (UTE and 129Xe).
Conditions Studied
Interventions
- DRUG 129Xe
Study Locations (3)
Kansas
- University of Kansas Medical Center - Kansas City
Ohio
- Carrie Stevens - Cincinnati
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2028-11-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05517655
The ClinicalTrials.gov registry entry for NCT05517655 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (75% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which 129Xe is the first listed.
NCT05517655 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Kansas, Ohio, Virginia.
Frequently Asked Questions
What is clinical trial NCT05517655 about?
NCT05517655 is a clinical study titled "BEGIN Novel ImagiNG Biomarkers". To determine the treatment effect of triple-combination therapy in 6-8 year olds after presumed FDA approval, using rapid structural and functional pulmonary and abdominal MRI (UTE and 129Xe).
What is the current status of trial NCT05517655?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2022-05-01. Estimated completion is 2028-11-01.
What conditions does trial NCT05517655 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT05517655?
The interventions under investigation include: 129Xe (DRUG).
Who is sponsoring clinical trial NCT05517655?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05517655 being conducted?
This trial has 3 study locations across Kansas, Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Markers of Osteoporosis in Cystic Fibrosis
RECRUITING · Phase 4
-
Estrogen Supplementation and Bone Health in Women With CF
RECRUITING · Phase 4
-
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
RECRUITING · Phase 4
-
Hyperpolarized Imaging for New Treatments
ACTIVE NOT RECRUITING · Phase 4
-
Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis
ACTIVE NOT RECRUITING · Phase 4
-
PR-018: An Open-Label, Safety Extension of Study PR-011
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.